

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: O'Brien et al

§ ART UNIT: 1642

FILED: October 20, 1999

§
§
§
§
§
§
§
§EXAMINER:
Harris, Alana.

SERIAL NO.: 09/421,213

CONFIRMATION NO. 3804

FOR: TADG-15: An Extracellular Serine
Protease Overexpressed in
Breast and Ovarian Carcinomas

DOCKET: D6064CIP

MS AF

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450RECEIVED
CENTRAL FAX CENTER

OCT 25 2004

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this Response after Final is being transmitted via facsimile to the
PTO fax center at 703-872-9306 on the date indicated below:

Date:


Oct 25, 2004
Benjamin Aaron Adler, Ph.D., J.D.RESPONSE AND AMENDMENT UNDER 37 C.F.R. 1.116

Dear Sir:

In response to the Final Office Action mailed July 27, 2004 for the
above-referenced application, please enter the following amendments and
consider the following remarks. Reconsideration of this pending claims is
respectfully requested.

Respectfully submitted,

Date:

10/25/04ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
713-270-5391
badler1@houston.rr.comBenjamin Aaron Adler, Ph.D., J.D.
Registration No. 35,423
Counsel for Applicant